



# TRANSMITTAL FORM


(to be used for all correspondence after initial filing)

		Application Number	09/721,341
		Filing Date	November 21, 2000
		First Named Inventor	Gosling, Jennifa et al.
		Art Unit	1647
		Examiner Name	Bunner, Bridget E.
Total Number of Pages in This Submission		Attorney Docket Number	019934-000711US

## ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input checked="" type="checkbox"/> Petition under 37 CFR 1.47(a) (including Attachments A-D) <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input checked="" type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): - Request to Correct Inventorship Under 37 CFR 1.48(a) - Declaration Under 37 CFR 1.48(a) - Declaration Under 37 CFR 1.48(a) – Dale Talbot - Declaration - 3.73(b) Statement - Consent of Assignee for Correction of Inventorship		
			<input type="checkbox"/> Remarks	The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT


Firm or Individual	Townsend and Townsend and Crew LLP Scott L. Ausenhus	
Signature		
Date	Reg. No. 42,271 November 29, 2004	

## CERTIFICATE OF TRANSMISSION/MAILING

Express Mail Label: EV 291376412 US

I hereby certify that this correspondence is being deposited with the United States Postal Service with "Express Mail Post Office to Address" service under 37 CFR 1.10 on this date November 29, 2004 and is addressed to:

Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Typed or printed name	Tara N. Damhoff		
Signature		Date	November 29, 2004

# FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 260)

## METHOD OF PAYMENT (check all that apply)

 Check  Credit Card  Money Order  Other  None  
 Deposit Account:

Deposit Account Number

20-1430

Deposit Account Name

Townsend and Townsend and Crew LLP

The Director is authorized to: (check all that apply)

 Charge fee(s) indicated below  Credit any overpayments  
 Charge any additional fee(s) or any underpayment of fee(s)  
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

## FEE CALCULATION

## 1. BASIC FILING FEE

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1)

(\$0)

## 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	-**	Extra Claims		Fee Paid
		Fee from below	Fee Paid	
Independent Claims	-**			
Multiple Dependent	-**			
		X		

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$0)

\*\*or number previously paid, if greater; For Reissues, see above

Complete if Known	
Application Number	09/721,341
Filing Date	November 21, 2000
First Named Inventor	Gosling, Jennifa
Examiner Name	Bunner, Bridget E.
Art Unit	1647
Attorney Docket No.	019934-000711US

## FEE CALCULATION (continued)


## 3. ADDITIONAL FEES

Large Entity	Fee Code	Fee (\$)	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid
	1051	130		2051	65	Surcharge - late filing fee or oath	
	1052	50		2052	25	Surcharge - late provisional filing fee or cover sheet	
	1053	130		1053	130	Non-English specification	
	1812	2,520		1812	2,520	For filing a request for reexamination	
	1804	920*		1804	920*	Requesting publication of SIR prior to Examiner action	
	1805	1,840*		1805	1,840*	Requesting publication of SIR after Examiner action	
	1251	110		2251	55	Extension for reply within first month	
	1252	420		2252	210	Extension for reply within second month	
	1253	950		2253	475	Extension for reply within third month	
	1254	1,480		2254	740	Extension for reply within fourth month	
	1255	2,010		2255	1,005	Extension for reply within fifth month	
	1401	330		2401	165	Notice of Appeal	
	1402	330		2402	165	Filing a brief in support of an appeal	
	1403	290		2403	145	Request for oral hearing	
	1451	1,510		1451	1,510	Petition to institute a public use proceeding	
	1452	110		2452	55	Petition to revive - unavoidable	
	1453	1,330		2453	665	Petition to revive - unintentional	
	1501	1,330		2501	665	Utility issue fee (or reissue)	
	1502	480		2502	240	Design issue fee	
	1503	640		2503	320	Plant issue fee	
	1460	130		1460	130	Petitions to the Commissioner	130
	1807	50		1807	50	Petitions related to provisional applications	
	1806	180		1806	180	Submission of Information Disclosure Stmt	
	8021	40		8021	40	Recording each patent assignment per property (times number of properties)	
	1809	770		2809	385	Filing a submission after final rejection (37 CFR § 1.129(a))	
	1810	770		2810	385	For each additional invention to be examined (37 CFR § 1.129(b))	
	1801	770		2801	385	Request for Continued Examination (RCE)	
	1802	900		1802	900	Request for expedited examination of a design application	
						Other fee (specify) Request to Correct Inventorship	130

\*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$260)

SUBMITTED BY		Complete (if applicable)			
Name (Print/Type)	Scott L. Ausenhus	Registration No. (Attorney/Agent)	42,271	Telephone	303-571-4000
Signature				Date	November 29, 2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.



"Express Mail" Label No. EV 291376412 US  
Date of Deposit November 29, 2004

IFW  
1647


PATENT  
Docket No.: 019934-000711US

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

**Mail Stop Issue Fee**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

By:

  
Tara N. Damhoff

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Jennifa Gosling et al.  
Application No.: 09/721,341

Filed: November 21, 2000

For: METHOD FOR IDENTIFYING A  
MODULATOR OF THE BINDING  
OF CCX CKR POLYPEPTIDE TO  
A CHEMOKINE (AMENDED)

Customer No: 20350

Confirmation No.: 5168

Examiner: Bunner, Bridget E.

Art Unit: 1647

**COMMUNICATION REGARDING  
CHANGE IN INVENTORSHIP**

**Mail Stop Issue Fee**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This paper and accompanying documents are filed to correct inventorship in this application, specifically to delete Dale Talbot as a named inventor, who was named as an inventor in error without deceptive intent.

In accordance with the requirements of 37 C.F.R. 1.48(a), the following documents are attached:

(1) Request to Correct Inventorship under 37 C.F.R. 1.48(a);

12/07/2004 GWORD01 0000005 201430 09721341

01 FC:1464

130.00 DA

- (2) Statement from Dale Talbot stating that it was through error without deceptive intent that he was named as an inventor in the above-identified patent application;
- (3) Executed declarations by joint inventors Jennifa Gosling, Daniel J. Dairaghi, Zhenhua Miao and Thomas J. Schall in accordance with 37 C.F.R. §1.63;
- (4) Statement Under 37 C.F.R 3.73(b) signed by Thomas J. Schall on behalf of ChemoCentryx, Inc.;
- (5) Written consent from the assignee, ChemoCentryx, Inc., to the change in inventorship; and
- (6) Authorization to deduct the request fee of \$130.00, pursuant to 37 C.F.R. §1.17(i), from Deposit Account No. 20-1430 of the undersigned.

Inventor Michael Hanley did not provide an executed declaration listing the correct inventors despite being provided with the documents necessary to effectuate the change in inventorship (i.e., copy of application, currently pending claims and new declaration listing the correct inventors) and being contacted multiple times regarding this matter, thus evidencing a refusal to sign the necessary new declaration. Accordingly, a petition under 37 C.F.R. 1.47(a) is also enclosed to change the inventorship when a joint inventor refuses to join in executing a declaration.

The Patent Office is authorized to charge all fees associated with the request for correction of inventorship and the petition under 37 C.F.R. 1.47(a) to Deposit Account No. 20-1430. Any other fees can also be charged to this Deposit Account.

Jennifa Gosling et al.  
Application No.: 09/721,341  
Page 3

PATENT

If the Examiner believes a telephone conference would expedite  
prosecution of this application, please telephone the undersigned at (303) 571-4000.

Respectfully submitted,

  
Scott L. Ausenhus  
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: (303) 571-4000  
Fax: (415) 576-0300  
SLA:sla  
60365459 v1



"Express Mail" Label No. EV 291376412 US  
Date of Deposit November 29, 2004

**PATENT**  
Attorney Docket No.: 019934-000711US

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

**Mail Stop Issue Fee**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

By: 

Tara N. Damhoff

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Jennifa Gosling et al.

Application No.: 09/721,341

Filed: November 21, 2000

For: METHOD FOR IDENTIFYING A  
MODULATOR OF THE  
BINDING OF CCX CKR  
POLYPEPTIDE TO A  
CHEMOKINE (AMENDED)

Customer No.: 20350

Confirmation No.: 5168

Examiner: Bunner, Bridget E.

Art Unit: 1647

REQUEST TO CORRECT  
INVENTORSHIP UNDER 37 C.F.R. §  
1.48(a)

**Mail Stop Issue Fee**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicant requests under 37 C.F.R. §1.48(a) to delete Dale Talbot as an inventor to the above-identified patent application.


As required by 37 C.F.R. §1.48(a), the following are submitted herewith:

- (1) Statement from Dale Talbot stating that it was through error without deceptive intent that he was named as an inventor in the above-identified patent application;

- (2) Executed declarations by joint inventors Jennifa Gosling, Daniel J. Dairaghi, Zhenhua Miao and Thomas J. Schall in accordance with 37 C.F.R. §1.63;
- (3) Statement Under 37 CFR 3.73(b) signed by Thomas J. Schall on behalf of ChemoCentry, Inc.; and
- (4) Written consent from the assignee, ChemoCentryx, Inc., to the change in Inventorship.

Please deduct the request fee of \$130.00, pursuant to 37 C.F.R. §1.17(i), from Deposit Account No. 20-1430 of the undersigned. Please charge any additional fees or credit overpayment to the above Deposit Account.

Respectfully submitted,



Scott L. Ausenhus  
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 303-571-4000  
Fax: 415-576-0300  
SLA:tnd  
60243207 v1



"Express Mail" Label No. EV 291376412 US

11.29.04

PATENT

Attorney Docket No.: 019934-000711US

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

By: 

Tara N. Damhoff

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Jennifa Gosling et al.

Application No.: 09/721,341

Filed: November 21, 2000

For: **METHOD FOR IDENTIFYING A  
MODULATOR OF THE  
BINDING OF CCX CKR  
POLYPEPTIDE TO A  
CHEMOKINE (AMENDED)**

Customer No.: 20350

Customer No.: 5168

Examiner: Bunner, Bridget E.

Art Unit: 1647

**DECLARATION UNDER 37 C.F.R. §1.48(a)**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

I, Dale Talbot, state that it was through error without deceptive intent that I was named as an inventor in the above-referenced patent application.

I agree to the correction of inventorship currently requested by the assignees of the above-referenced patent to delete myself, Dale Talbot, as a joint inventor.

Dated: July 14, 2004

By



Dale Talbot

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 303-571-4000  
Fax: 415-576-0300  
SLA:tnd

**DECLARATION**

As a below named inventor, I declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: METHOD FOR IDENTIFYING A MODULATOR OF THE BINDING OF CCX CKR POLYPEPTIDE TO A CHEMOKINE (AMENDED) the specification of which \_\_\_\_\_ is attached hereto or X was filed on November 21, 2000 as Application No. 09/721,341 and was amended on August 1, 2001, January 30, 2002, May 28, 2002, November 26, 2002, May 12, 2003 and January 20, 2004.

I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56. I claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

**Prior Foreign Application(s)**

Country	Application No.	Date of Filing	Priority Claimed Under 35 USC 119

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:

Application No.	Filing Date
60/159,015	10/12/99
60/159,210	10/13/99
60/172,979	12/20/99
60/173,388	12/28/99
60/186,626	03/03/00


I claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Date of Filing	Status
09/686,020	10/10/00	Pending

Full Name of Inventor 1:	Last Name: <b>GOSLING</b>	First Name: <b>JENNIFA</b>	Middle Name or Initial:
Residence & Citizenship:	City: <b>San Francisco</b>	State/Foreign Country: <b>California</b>	Country of Citizenship: <b>United States</b>
Post Office Address:	Post Office Address: <b>322 Virginia Avenue</b>	City: <b>San Francisco</b>	State/Country: <b>California</b> Postal Code: <b>94110</b>






Full Name of Inventor 2:	Last Name: <b>DAIRAGHI</b>	First Name: <b>DANIEL</b>	Middle Name or Initial: <b>J.</b>
Residence & Citizenship:	City: <b>Palo Alto</b>	State/Foreign Country: <b>California</b>	Country of Citizenship: <b>United States</b>
Post Office Address:	Post Office Address: <b>178 El Dorado</b>	City: <b>Palo Alto</b>	State/Country: <b>California</b> Postal Code: <b>94306</b>
Full Name of Inventor 3:	Last Name: <b>HANLEY</b>	First Name: <b>MICHAEL</b>	Middle Name or Initial:
Residence & Citizenship:	City: <b>Corte Madera</b>	State/Foreign Country: <b>California</b>	Country of Citizenship: <b>United States</b>
Post Office Address:	Post Office Address: <b>81 Parkview Circle</b>	City: <b>Corte Madera</b>	State/Country: <b>California</b> Postal Code: <b>94925</b>
Full Name of Inventor 4:	Last Name: <b>MIAO</b>	First Name: <b>ZHENHUA</b>	Middle Name or Initial:
Residence & Citizenship:	City: <b>San Jose</b>	State/Foreign Country: <b>California</b>	Country of Citizenship: <b>Peoples Republic of China</b>
Post Office Address:	Post Office Address: <b>7070 Rainbow Drive, #2</b>	City: <b>San Jose</b>	State/Country: <b>California</b> Postal Code: <b>95129</b>
Full Name of Inventor 5:	Last Name: <b>SCHALL</b>	First Name: <b>THOMAS</b>	Middle Name or Initial: <b>J.</b>
Residence & Citizenship:	City: <b>Palo Alto</b>	State/Foreign Country: <b>California</b>	Country of Citizenship: <b>United States</b>
Post Office Address:	Post Office Address: <b>563 Homer Ave.</b>	City: <b>Palo Alto</b>	State/Country: <b>California</b> Postal Code: <b>94301</b>

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1  Jennifer Gosling Date <u>6.28.2004</u>	Signature of Inventor 2 Daniel J. Dairaghi Date _____	Signature of Inventor 3 Michael Hanley Date _____
Signature of Inventor 4 Zhenhua Miao Date _____	Signature of Inventor 5 Thomas J. Schall Date _____	

Full Name of Inventor 2:	Last Name: <b>DAIRAGHI</b>	First Name: <b>DANIEL</b>	Middle Name or Initial: <b>J.</b>
Residence & Citizenship:	City: <b>Palo Alto</b>	State/Foreign Country: <b>California</b>	Country of Citizenship: <b>United States</b>
Post Office Address:	Post Office Address: <b>178 El Dorado</b>	City: <b>Palo Alto</b>	State/Country: <b>California</b> Postal Code: <b>94306</b>
Full Name of Inventor 3:	Last Name: <b>HANLEY</b>	First Name: <b>MICHAEL</b>	Middle Name or Initial:
Residence & Citizenship:	City: <b>Corte Madera</b>	State/Foreign Country: <b>California</b>	Country of Citizenship: <b>United States</b>
Post Office Address:	Post Office Address: <b>81 Parkview Circle</b>	City: <b>Corte Madera</b>	State/Country: <b>California</b> Postal Code: <b>94925</b>
Full Name of Inventor 4:	Last Name: <b>MIAO</b>	First Name: <b>ZHENHUA</b>	Middle Name or Initial:
Residence & Citizenship:	City: <b>San Jose</b>	State/Foreign Country: <b>California</b>	Country of Citizenship: <b>Peoples Republic of China</b>
Post Office Address:	Post Office Address: <b>7070 Rainbow Drive, #2</b>	City: <b>San Jose</b>	State/Country: <b>California</b> Postal Code: <b>95129</b>
Full Name of Inventor 5:	Last Name: <b>SCHALL</b>	First Name: <b>THOMAS</b>	Middle Name or Initial: <b>J.</b>
Residence & Citizenship:	City: <b>Palo Alto</b>	State/Foreign Country: <b>California</b>	Country of Citizenship: <b>United States</b>
Post Office Address:	Post Office Address: <b>563 Homer Ave.</b>	City: <b>Palo Alto</b>	State/Country: <b>California</b> Postal Code: <b>94301</b>

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1  Jennifa Gosling Date _____	Signature of Inventor 2  Daniel J. Dairaghi Date <u>23 June 2004</u>	Signature of Inventor 3  Michael Hanley Date _____
Signature of Inventor 4  Zhenhua Miao Date <u>6/29/04</u>	Signature of Inventor 5  Thomas J. Schall Date <u>7/2/04</u>	



"Express Mail" Label No. EV 291376412 US

Date of Deposit 11-29-04

PATENT  
Attorney Docket No.: 019934-000711US

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

By: 

Tara N. Damhoff

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jennifa Gosling et al.

Application No.: 09/721,341

Filed: November 21, 2000

For: METHOD FOR IDENTIFYING A  
MODULATOR OF THE  
BINDING OF CCX CKR  
POLYPEPTIDE TO A  
CHEMOKINE (AMENDED)

Customer No.: 20350

Customer No.: 5168

Examiner: Bunner, Bridget E.

Art Unit: 1647

CONSENT OF ASSIGNEE FOR  
CORRECTION OF INVENTORSHIP  
UNDER 37 C.F.R. § 1.48(a)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The assignee of the above-identified patent application, ChemoCentryx, Inc., consents to amending the subject application to delete Dale Talbot as an inventor.

In accordance with 37 C.F.R. §3.73(b), a certificate of assignment is enclosed to establish ownership of the above-identified application by ChemoCentryx, Inc.

**CHEMOCENTRYX, INC.**

6/30/04  
Date

By:   
Name: Thomas J. Schall  
Title: President and CEO

**STATEMENT UNDER 37 CFR 3.73(b)**

Applicant/Patent Owner: Jennifa Gosling, Daniel J. Dairaghi, Michael Hanley, Zhenhua Miao, Thomas J. Schall  
(applicants as corrected)

Application No./Patent No.: 09/721,341 Filed/Issue Date: November 21, 2000

Entitled: METHOD FOR IDENTIFYING A MODULATOR OF THE BINDING OF CCX CKR POLYPEPTIDE TO A CHEMOKINE (AMENDED)

ChemoCentryx, Inc. a Delaware corporation  
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1.  the assignee of the entire right, title, and interest; or
2.  an assignee of less than the entire right, title and interest.

The extent (by, percentage) of its ownership interest is        %

in the patent application/patent identified above by virtue of either:

A.  An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 011909, Frame 0816, or for which a copy thereof is attached.

**OR**

B.  A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: \_\_\_\_\_ To : \_\_\_\_\_

The document was recorded in the United States Patent and Trademark Office at  
Reel       , Frame       , or for which a copy thereof is attached.

2. From: \_\_\_\_\_ To : \_\_\_\_\_

The document was recorded in the United States Patent and Trademark Office at  
Reel       , Frame       , or for which a copy thereof is attached.

3. From: \_\_\_\_\_ To : \_\_\_\_\_

The document was recorded in the United States Patent and Trademark Office at  
Reel       , Frame       , or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet.

Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.8]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

6/30/04


Date

650-632-2900

Telephone number

Thomas J. Schall

Typed or printed name



Signature

President and Chief Executive Officer

Title



"Express Mail" Label No. EV 291376412 US  
Date of Deposit November 29, 2004

**PATENT**  
Docket No.: 019934-000711US

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

**Mail Stop Issue Fee**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

By: Tara N. Damhoff  
Tara N. Damhoff

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jennifa Gosling et al.  
Application No.: 09/721,341  
Filed: November 21, 2000

For: METHOD FOR IDENTIFYING A  
MODULATOR OF THE BINDING  
OF CCX CKR POLYPEPTIDE TO  
A CHEMOKINE (AMENDED)

Customer No.: 20350

Confirmation No.: 5168

Examiner: Bunner, Bridget E.  
Art Unit: 1647

PETITION UNDER 37 C.F.R. 1.47(a)

**Mail Stop Issue Fee**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 C.F.R. 1.47(a), Applicants hereby petition for entry of the new declaration that is enclosed. This new declaration is provided as part of a request for correction of inventorship under 37 C.F.R. 1.48(a). As indicated in the enclosed request, Applicants are petitioning for deletion of Dale Talbot as a named inventor. Inventor Michael Hanley, however, has refused to sign the new declaration that is required under 37 C.F.R. 1.48(a), despite multiple attempts to contact Mr. Hanley. In

this regard, Applicants note that the deleted inventor, Dale Talbot, has executed the necessary documents to effectuate the change in inventorship.

Statement of Facts

As required for a petition under 37 C.F.R. 1.47(a), the undersigned provides the following statement of facts evidencing a refusal by Michael Hanley to sign the new declaration:

(1) On June 22, 2004, a letter (Attachment A) was sent to Mr. Hanley at his business address (see below) by FedEx requesting that he sign a new declaration to remove Dale Talbot as inventor. The letter enclosed a copy of the application (referred to in the letter as the 019934-000710 application), a copy of the claims as currently pending, and a copy of the new declaration for signature by Mr. Hanley. A copy of a FedEx delivery receipt (Attachment B) is enclosed, confirming delivery of the materials to Mr. Hanley's place of employment on June 23, 2004.

(2) On July 15, 2004, after not receiving the executed declaration, the undersigned's secretary tried contacting Mr. Hanley and spoke with Mr. Hanley's secretary. Mr. Hanley's secretary confirmed that Mr. Hanley had received the materials and stated that Mr. Hanley considered this matter a low priority and would attend to it when he had time.

(3) On August 11, 2004, the undersigned sent another letter (Attachment C) to Mr. Hanley at his business address reminding Mr. Hanley of the need for the new declaration and noting that the necessary documents from all the other inventors had been received. A copy of a FedEx delivery receipt (Attachment D) is enclosed, confirming delivery of the materials to Mr. Hanley's place of employment on August 12, 2004.

(4) On October 19, 2004, the undersigned tried calling Mr. Hanley and reached his secretary, Rosemary, who said that she would leave a message with Mr. Hanley to contact the undersigned to discuss this patent matter.

(5) On October 20, 2004, the undersigned called Mr. Hanley and again reached his secretary, Rosemary. Mr. Hanley's secretary confirmed that she had relayed the undersigned's previous message to Mr. Hanley and said she would again remind Mr. Hanley to contact the undersigned.

(6) After not hearing from Mr. Hanley, the undersigned again called Mr. Hanley on October 26, 2004 and this time reached Mr. Hanley's personal voicemail rather than Mr. Hanley's secretary. The undersigned left a message requesting Mr. Hanley to call about changing inventorship in this application and noting that all the other inventors had signed the necessary documents. Mr. Hanley never returned the undersigned's calls.

Applicants submit that this chronology of events clearly demonstrate that Mr. Hanley was provided with the necessary documents (including application, currently pending claims and new declaration) to correct inventorship in this application and his refusal to execute the necessary declaration. Applicants thus request that this petition under 37 C.F.R. 1.47(a) be granted and that the enclosed new declaration signed by all the other correct inventors be entered into the file as part of the enclosed request to correct inventorship (i.e., to delete Dale Talbot as inventor, thus leaving Jennifa Gosling, Daniel J. Dairaghi, Michael Hanley, Zhenhua Miao and Thomas J. Schall as the correct inventors).

Last Known Address

Applicants are only aware of Mr. Hanley's current business address, which is Amylin Pharmaceuticals, Inc., 9360 Towne Center Drive, Ste. 110, San Diego, CA 92121.

Petition Fee

The Patent Office is authorized to charge the petition fee under 37 C.F.R. 1.17(h) to Deposit Account No. 20-1430, as well as any other fee that may be due as part of the processing of this petition.


Jennifa Gosling et al.  
Application No.: 09/721,341  
Page 4

PATENT

If this petition is more properly brought under 37 C.F.R. 1.183, then Applicants request that this petition be treated as such and that the necessary fees for such a petition be charged to Deposit Account No. 20-1430, as well as any other fee that may be due as part of the processing of this petition.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at (303)571-4000.

Respectfully submitted,



Scott L. Ausenhus  
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: (303)571-4000  
Fax: (415) 576-0300  
SLA:sla

60365460 v1

Attachment A

TOWNSEND  
and  
TOWNSEND  
and  
CREW  
LLP



June 22, 2004

**VIA FEDEX**

Michael Hanley, Ph.D.  
Vice President Discovery Research  
Amylin Pharmaceuticals, Inc.  
9360 Towne Centre Drive, Ste. 110  
San Diego, CA 92121

Re: ChemoCentryx Patent Applications  
Our File No.: 019934-000710US  
Our File No.: 019934-000711US  
Our File No.: 019934-000723US

Dear Dr. Hanley:

I am a patent attorney and am currently assisting ChemoCentryx, Inc. with the above-referenced patent applications.

ChemoCentryx has undertaken a review of the inventors listed in these applications to evaluate whether inventorship needs to be altered in view of the pending claims. It was determined that inventorship should be altered in these applications as indicated below:

Our Files 019934-000711US and -000723US: Remove Dale Talbot as inventor;

Our File 019934-000710US: Remove Dale Talbot and yourself as inventors.

A copy of the 019934-000710US and -000723US applications as filed and the claims as currently pending in each application are also enclosed for your reference (the 019934-000711US application is identical to the -000710US application and thus is not included). These documents are of course confidential and should not be disclosed to anyone else.

After reviewing the applications and claims, please sign and DATE the enclosed documents and return them and the enclosures to me as soon as possible in the Federal Express envelope that is enclosed for your convenience. The documents that are enclosed include:

Our Files 019934-000711US and -000723US: A new declaration listing the correct inventors. This declaration should be signed and DATED by you in the spaces provided. The other inventors will sign other copies of the declaration.

San Francisco, California  
Tel 415 576-0200

Denver

1200 Seventeenth Street  
Suite 2700  
Denver  
Colorado 80202-5827  
Tel 303 571-4000  
Fax 303 571-4321

Palo Alto, California  
Tel 650 326-2400

Walnut Creek, California  
Tel 925 472-5000

San Diego, California  
Tel 858-350-6100

Seattle, Washington  
Tel 206 467-9600


TOWNSEND  
and  
TOWNSEND  
and  
CREW  
LLP

Michael Hanley, Ph.D.  
June 22, 2004  
Page 2

Our File 019934-000710US: A statement by you requesting a change of inventorship.

ChemoCentryx appreciates your assistance in this matter. Please do not hesitate to contact me if you have any questions or concerns regarding this matter.

Very truly yours,



Scott L. Ausenhus

SLA/tnd

Enclosures

cc: Mark Penfold, ChemoCentryx, Inc. (*Via Federal Express, w/o Enclosures*)  
60245259 v1

**Damhoff, Tara N.**

---

**From:** FedEx [donotreply@fedex.com]  
**Sent:** Wednesday, June 23, 2004 11:14 AM  
**To:** Damhoff, Tara N.  
**Subject:** FedEx shipment 790677235553

Our records indicate that the shipment sent from Scott Ausenhus/Townsend & Townsend & Cre to Michael Hanley, Ph.D./Amylin Pharmaceuti has been delivered.  
The package was delivered on 06/23/2004 at 9:39 AM and signed for or released by E.MOLINA.

The ship date of the shipment was 06/22/2004.

The tracking number of this shipment was 790677235553.

FedEx appreciates your business. For more information about FedEx services, please visit our web site at <http://www.fedex.com>

To track the status of this shipment online please use the following:  
[http://www.fedex.com/cgi-bin/tracking?tracknumbers=790677235553&action=track&language=english&cntry\\_code=us](http://www.fedex.com/cgi-bin/tracking?tracknumbers=790677235553&action=track&language=english&cntry_code=us)

**Disclaimer**

---

FedEx has not validated the authenticity of any email address.

**TOWNSEND**  
 and  
**TOWNSEND**  
 and  
**CREW**  
 LLP

San Francisco, California  
 Tel 415 576-0200

**Denver**

Palo Alto, California  
 Tel 650 326-2400

1200 Seventeenth Street  
 Suite 2700  
 Denver  
 Colorado 80202-5827  
 Tel 303 571-4000  
 Fax 303 571-4321

Walnut Creek, California  
 Tel 925 472-5000

San Diego, California  
 Tel 858-350-6100

Seattle, Washington  
 Tel 206 467-9600

August 11, 2004

**VIA FEDEX**

Michael Hanley, Ph.D.  
 Vice President Discovery Research  
 Amylin Pharmaceuticals, Inc.  
 9360 Towne Centre Drive, Ste. 110  
 San Diego, CA 92121

Re: ChemoCentryx Patent Applications  
 Our File No.: 019934-000710US  
 Our File No.: 019934-000711US  
Our File No.: 019934-000723US

Dear Dr. Hanley:

As I indicated in my earlier letter to you dated June 22, 2004, ChemoCentryx Inc. is requesting your cooperation in correcting the inventorship in these three applications. We have received the necessary papers from all the other inventors, and are now just awaiting the papers from you.

To elaborate somewhat on my earlier letter, and as you can see from the applications and claims I provided you previously, the subject matter of the foregoing applications falls into two categories:

1. The 019934-000711US and -000723US applications, which are directed to screening methods to identify agents that modulate the activity of the chemokine receptor CCX CKR. ChemoCentryx has concluded that you are an inventor of the claims in these applications and thus simply needs you to sign the papers I provided you for these applications to have Mr. Dale Talbot removed as a named inventor. Mr. Talbot has already agreed to this change and sent us the necessary formal documents he needed to sign to effectuate this change.

2. The 019934-000710US application, which is directed to methods of treating a CCX CKR medicated condition in a mammal. ChemoCentryx has concluded that the work underlying this invention was performed by others after your departure from ChemoCentryx. The papers I provided you with previously thus are to remove Mr. Talbot and yourself as named inventors. Again, Mr. Talbot has already signed the appropriate papers.

If you have any questions or concerns about this matter or need another copy of the applications and claims that were sent with my letter dated June 22, 2004, please do not hesitate to contact me. Upon receipt of the documents from you we can conclude this matter.

TOWNSEND  
and  
TOWNSEND  
and  
CREW  
LLP

Michael Hanley, Ph.D.  
August 11, 2004  
Page 2

Once again, ChemoCentryx would like to thank you in advance for your cooperation in this matter.

Very truly yours,



Scott L. Ausenhus

SLA/tnd

cc: Mark Penfold, ChemoCentryx, Inc. (*Via U.S. Mail*)  
60245259 v1

**Damhoff, Tara N.**

---

**From:** FedEx [donotreply@fedex.com]  
**Sent:** Thursday, August 12, 2004 12:55 PM  
**To:** Damhoff, Tara N.  
**Subject:** FedEx shipment 790729963781

Our records indicate that the shipment sent from Scott Ausenhus/Townsend & Townsend & Cre to Michael Hanley, Ph.D./Amylin Pharmaceuti has been delivered.  
The package was delivered on 08/12/2004 at 9:42 AM and signed for or released by E.MOLINA.

The ship date of the shipment was 08/11/2004.

The tracking number of this shipment was 790729963781.

FedEx appreciates your business. For more information about FedEx services, please visit our web site at <http://www.fedex.com>

To track the status of this shipment online please use the following:  
[http://www.fedex.com/cgi-bin/tracking?tracknumbers=790729963781&action=track&language=english&cntry\\_code=us](http://www.fedex.com/cgi-bin/tracking?tracknumbers=790729963781&action=track&language=english&cntry_code=us)

**Disclaimer**

---

FedEx has not validated the authenticity of any email address.